These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 30692318)
1. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis]. Okazaki M; Tajima H; Ohbatake Y; Terai S; Nakanuma S; Okamoto K; Sakai S; Makino I; Kinoshita J; Nakamura K; Miyashita T; Takamura H; Ninomiya I; Fushida S; Ohta T Gan To Kagaku Ryoho; 2018 Dec; 45(13):2162-2164. PubMed ID: 30692318 [TBL] [Abstract][Full Text] [Related]
2. Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338 [TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653 [TBL] [Abstract][Full Text] [Related]
4. [A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer]. Ohno N; Ishida M; Ohnishi K; Sawai K; Tabata S; Deguchi M; Kitajima T; Kaizaki Y Gan To Kagaku Ryoho; 2017 Nov; 44(12):1735-1738. PubMed ID: 29394759 [TBL] [Abstract][Full Text] [Related]
5. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943 [TBL] [Abstract][Full Text] [Related]
6. [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. Katsura Y; Takeda Y; Ohmura Y; Motoyama Y; Ishida T; Morimoto Y; Matsushita K; Naito A; Murakami K; Kagawa Y; Okishiro M; Takeno A; Egawa C; Kato T; Tamura S Gan To Kagaku Ryoho; 2015 Nov; 42(12):2367-9. PubMed ID: 26805366 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517 [TBL] [Abstract][Full Text] [Related]
8. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report]. Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678 [TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079 [TBL] [Abstract][Full Text] [Related]
11. GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report. Yoshii H; Izumi H; Abe R; Tajiri T; Mukai M; Nomura E; Makuuchi H Tokai J Exp Clin Med; 2019 Dec; 44(4):85-89. PubMed ID: 31768996 [TBL] [Abstract][Full Text] [Related]
12. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine. Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696 [TBL] [Abstract][Full Text] [Related]
14. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Kawaida H; Kono H; Amemiya H; Saitou R; Yamamoto A; Hosomura N; Watanabe M; Kimura A; Furuya S; Shimizu H; Akaike H; Kawaguchi Y; Sudo M; Itakura J; Hayakawa H; Shindo H; Takahashi EI; Takano S; Fukasawa M; Ichikawa S; Fujii H; Ichikawa D Anticancer Res; 2018 Nov; 38(11):6537-6542. PubMed ID: 30396983 [TBL] [Abstract][Full Text] [Related]
15. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial). Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H; Oncology; 2017; 93(5):343-346. PubMed ID: 28719890 [TBL] [Abstract][Full Text] [Related]
16. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842 [TBL] [Abstract][Full Text] [Related]
17. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366 [TBL] [Abstract][Full Text] [Related]
18. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Youn S; Chen A; Ha V; Chambers C; Eurich DT; McCall M; Sawyer MB Clin Nutr; 2021 Aug; 40(8):4888-4892. PubMed ID: 34358833 [TBL] [Abstract][Full Text] [Related]
19. The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Barbour AP; Samra JS; Haghighi KS; Donoghoe MW; Burge M; Harris MT; Chua YJ; Mitchell J; O'Rourke N; Chan H; Gebski VJ; Gananadha S; Croagh DG; Kench JG; Goldstein D; Ann Surg Oncol; 2020 Jul; 27(7):2506-2515. PubMed ID: 31997125 [TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]